Goodwin Procter recently advised client Unum Therapeutics on two significant transactions. On June 8, Goodwin advised Unum on its strategic collaboration and license agreement with Seattle Genetics (Nasdaq: SGEN) to develop and commercialize ACTR therapies for cancer. The firm also advised Unum on its $65 million Series B financing announced June 11. New Leaf Venture Partners, one of eight new investors, led the round; existing investors also participated in the oversubscribed funding.
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. The company’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase 1 clinical testing to assess safety and efficacy. The company is headquartered in Cambridge, Mass.
To learn more about Unum’s partnership with Seattle Genetics, please read the June 8 press release. Additional information regarding the company’s latest round of funding is available in Unum’s June 11 press release.